Superficial bladder cancer

被引：15
作者：
Lamm D.L. [1 ]
机构：
[1] Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, 85259, AZ
来源：
Current Treatment Options in Oncology | 2002年 / 3卷 / 5期
关键词：
Bladder Cancer; Contraindication Hypersensitivity; Main Drug Interaction; Superficial Bladder Cancer; Thiotepa;
D O I：
10.1007/s11864-002-0005-4
中图分类号：
学科分类号：
摘要：
Superficial bladder cancer can be resected with minimal morbidity, but the patients are at high risk for tumor recurrence. Tumors can be divided into low-, intermediate-, and high-risk categories based on tumor grade, stage, and pattern of recurrence. Low-risk tumors are best treated with a single instillation of chemotherapy such as thiotepa, doxorubicin, or mitomycin. Intermediate-risk tumors can be treated with chemotherapy, but, similar to high-risk tumors, will often require immunotherapy. High-risk tumors are best treated with intravesical bacille Calmette-Guerin (BCG) using a 3-week maintenance schedule. Side effects of BCG immunotherapy can be reduced by logarithmic reductions in the dosage of BCG. Patients who fail BCG may be rescued with BCG plus interferon-alfa or radical cystectomy. © 2002, Current Science Inc.
引用
收藏
页码：403 / 411
页数：8
相关论文
共 20 条
  • [1] Dalbagni G., Genega E., Hashibe M., Et al., Cystectomy for bladder cancer: a contemporary series, J Urol, 165, pp. 1111-1116, (2001)
  • [2] Lamm D.L., Griffith J.G., Intravesical therapy: does it affect the natural history of superficial bladder cancer?, Semin Urol, 10, pp. 39-44, (1992)
  • [3] Heney N.M., Natural history of superficial bladder cancer: prognostic features and long-term disease course, Urol Clin North Am, 19, pp. 429-433, (1992)
  • [4] Vicente J., Laguna M.P., Duarte D., Algaba F., Chechile G., Carcinoma in situ as a prognostic factor for G3pT1 bladder tumours, Br J Urol, 68, pp. 380-382, (1991)
  • [5] Bostwick D.G., Natural history of early bladder cancer, J Cell Biochem, 161, pp. 31-38, (1992)
  • [6] Fleshner N., Moadel A., Herr H., Et al., Influence of smoking status on outcomes in patients with tobacco-associated superficial transitional cell carcinoma of the bladder, Cancer, 86, pp. 2337-2345, (1999)
  • [7] Byar D., Blackard D., Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer, Urology, 10, pp. 556-561, (1977)
  • [8] Kamat A.M., Lamm D.L., Chemoprevention of urological cancer [comment], J Urol, 163, (2000)
  • [9] Lamm D.L., Riggs D.R., Shriver J.S., Et al., Megadose vitamins in bladder cancer: a double-blind clinical trial, J Urol, 151, pp. 21-26, (1994)
  • [10] Pawinski A., Sylvester R., Kurth K.H., Et al., A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer, J Urol, 156, pp. 1934-1940, (2002)
12